Genmab | GEN - Cash And Equivalent


Genmab reported DKK1.72B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Amarin USD 131.06M 3.6M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
argenx SE USD 4.3B 808.71M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Demant DKK 1.33B 188M Dec/2025
Exelixis USD 226.15M 256.34M Mar/2026
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GN Store Nord DKK 1.12B 352M Dec/2025
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Insmed USD 582.19M 71.74M Mar/2026
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.33B 77M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024